These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 34802443)

  • 1. m
    Zhang Z; Zhang C; Luo Y; Wu P; Zhang G; Zeng Q; Wang L; Yang Z; Xue L; Zheng B; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
    BMC Med; 2021 Nov; 19(1):284. PubMed ID: 34802443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m
    Zhang Z; Zhang C; Yang Z; Zhang G; Wu P; Luo Y; Zeng Q; Wang L; Xue Q; Zhang Y; Sun N; He J
    J Hematol Oncol; 2021 Nov; 14(1):190. PubMed ID: 34758859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.
    Wang L; Wu P; Shen Z; Yu Q; Zhang Y; Ye F; Chen K; Zhao J
    Int Immunopharmacol; 2023 Apr; 117():109827. PubMed ID: 36989973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analyses of N
    Luo Y; Zhang Z; Zheng B; Wu P; Zhang G; Wang L; Zeng Q; Yang Z; Xue L; Zeng H; Tan F; Xue Q; Gao S; Sun N; He J
    Cancer Sci; 2022 Dec; 113(12):4289-4299. PubMed ID: 36047973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Necrosis Factor Family Member Profile Predicts Prognosis and Adjuvant Chemotherapy Benefit for Patients With Small-Cell Lung Cancer.
    Zhang Z; Wu P; Zhang C; Luo Y; Zhang G; Zeng Q; Wang L; Yang Z; Sun N; He J
    Front Immunol; 2021; 12():745769. PubMed ID: 34867972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of baseline clinicopathological characteristics in first-line chemotherapy ± immunotherapy for extensive-stage small cell lung cancer: a retrospective cohort study.
    Wu Y; Ye J; Shao Z; Rossi A; Chen Y; Li Y; Wu S
    J Thorac Dis; 2024 Aug; 16(8):5348-5360. PubMed ID: 39268133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.
    Liu X; Xing H; Zhang H; Liu H; Chen J
    Immunotherapy; 2021 Aug; 13(12):989-1000. PubMed ID: 34114477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer.
    Wu P; Zhang Z; Yang Z; Zhang C; Luo Y; Zhang G; Wang L; Xue Q; Sun N; He J
    Cancer Immunol Immunother; 2023 Mar; 72(3):617-631. PubMed ID: 36002754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy.
    Jiang Y; Xie J; Cheng Q; Cai Z; Xu K; Lu W; Wang F; Wu X; Song Y; Lv T; Zhan P
    Int Immunopharmacol; 2024 Nov; 141():112901. PubMed ID: 39151386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
    Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
    J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immune-related lncRNA signature predicts prognosis and adjuvant chemotherapeutic response in patients with small-cell lung cancer.
    Zhang Z; Luo Y; Zhang C; Wu P; Zhang G; Zeng Q; Wang L; Xue L; Yang Z; Zeng H; Zheng B; Tan F; Xue Q; Gao S; Sun N; He J
    Cancer Cell Int; 2021 Dec; 21(1):691. PubMed ID: 34930244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

  • 16. Unravelling the biology of SCLC: implications for therapy.
    Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
    Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy.
    Bi N; Cao J; Song Y; Shen J; Liu W; Fan J; He J; Shi Y; Zhang X; Lu N; Zhan Q; Wang L
    PLoS One; 2014; 9(3):e91388. PubMed ID: 24637927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
    Shijubou N; Sumi T; Kubo T; Sasaki K; Tsukahara T; Kanaseki T; Murata K; Keira Y; Terai K; Ikeda T; Yamada Y; Chiba H; Hirohashi Y; Torigoe T
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):125. PubMed ID: 38483588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.
    Jiang Y; Chen Y; Cheng Q; Lu W; Li Y; Zuo X; Wu Q; Wang X; Zhang F; Wang D; Wang Q; Lv T; Song Y; Zhan P
    Cancer Immunol Immunother; 2024 Oct; 73(12):241. PubMed ID: 39358575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.